Table of Content

1. Executive Summary
   1.1. Global CAR T-Cell Therapy Market Snapshot, 2024 and 2031
   1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
   1.3. Key Market Trends
   1.4. Future Market Projections
   1.5. Premium Market Insights
   1.6. Industry Developments and Key Market Events
   1.7. PMR Analysis and Recommendations
2. Market Overview
   2.1. Market Scope and Definition
   2.2. Market Dynamics
       2.2.1. Drivers
       2.2.2. Restraints
       2.2.3. Opportunity
       2.2.4. Key Trends
   2.3. Macro-Economic Factors
       2.3.1. Global Sectorial Outlook
       2.3.2. Global GDP Growth Outlook
   2.4. COVID-19 Impact Analysis
   2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
   3.1. Product Adoption Analysis
   3.2. Regulatory Landscape
   3.3. Pipeline Analysis
   3.4. Value Chain Analysis
   3.5. PESTLE Analysis
   3.6. Porter’s Five Force Analysis
   3.7. Parent Market Analysis
4. Global CAR T-Cell Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   4.1. Key Highlights
       4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
       4.1.2. Absolute $ Opportunity
   4.2. Market Size (US$ Mn) Analysis and Forecast
       4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2022
       4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2023-2031
   4.3. Global CAR T-Cell Therapy Market Outlook: Product
       4.3.1. Introduction / Key Findings
       4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019 - 2022
       4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2023 - 2031
           4.3.3.1. Yescarta (axicabtagene ciloleucel)
           4.3.3.2. Kymriah (tisagenlecleucel)
           4.3.3.3. JCAR017 (lisocabtagene maraleucel)
           4.3.3.4. bb2121
       4.3.4. Market Attractiveness Analysis: Product
   4.4. Global CAR T-Cell Therapy Market Outlook: Indication
       4.4.1. Introduction / Key Findings
       4.4.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2019 - 2022
       4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
           4.4.3.1. Relapsed Large B-cell Lymphoma
           4.4.3.2. Acute Lymphoblastic Leukemia (ALL)
           4.4.3.3. Multiple Myeloma
       4.4.4. Market Attractiveness Analysis: Indication
   4.5. Global CAR T-Cell Therapy Market Outlook: End User
       4.5.1. Introduction / Key Findings
       4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019 - 2022
       4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2023 - 2031
           4.5.3.1. Car T-Cell Therapy at Hospitals
           4.5.3.2. Car T-Cell Therapy at Cancer Treatment Centers
       4.5.4. Market Attractiveness Analysis: End User
5. Global CAR T-Cell Therapy Market Outlook: Region
   5.1. Key Highlights
   5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019 - 2022
   5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2023 - 2031
       5.3.1. North America
       5.3.2. Europe
       5.3.3. East Asia
       5.3.4. South Asia and Oceania
       5.3.5. Latin America
       5.3.6. Middle East & Africa
   5.4. Market Attractiveness Analysis: Region
6. North America CAR T-Cell Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   6.1. Key Highlights
   6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       6.2.1. By Country
       6.2.2. By Product
       6.2.3. By Indication
       6.2.4. By End User
   6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
       6.3.1. U.S.
       6.3.2. Canada
   6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2023 - 2031
       6.4.1. Yescarta (axicabtagene ciloleucel)
       6.4.2. Kymriah (tisagenlecleucel)
       6.4.3. JCAR017 (lisocabtagene maraleucel)
       6.4.4. bb2121
   6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       6.5.1. Relapsed Large B-cell Lymphoma
       6.5.2. Acute Lymphoblastic Leukemia (ALL)
       6.5.3. Multiple Myeloma
   6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2023 - 2031
       6.6.1. Car T-Cell Therapy at Hospitals
       6.6.2. Car T-Cell Therapy at Cancer Treatment Centers
   6.7. Market Attractiveness Analysis
7. Europe CAR T-Cell Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   7.1. Key Highlights
   7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       7.2.1. By Country
       7.2.2. By Product
       7.2.3. By Indication
       7.2.4. By End User
   7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
       7.3.1. Germany
       7.3.2. France
       7.3.3. U.K.
       7.3.4. Italy
       7.3.5. Spain
       7.3.6. Russia
       7.3.7. Türkiye
       7.3.8. Rest of Europe
   7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2023 - 2031
       7.4.1. Yescarta (axicabtagene ciloleucel)
       7.4.2. Kymriah (tisagenlecleucel)
       7.4.3. JCAR017 (lisocabtagene maraleucel)
       7.4.4. bb2121
   7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       7.5.1. Relapsed Large B-cell Lymphoma
       7.5.2. Acute Lymphoblastic Leukemia (ALL)
       7.5.3. Multiple Myeloma
   7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2023 - 2031
       7.6.1. Car T-Cell Therapy at Hospitals
       7.6.2. Car T-Cell Therapy at Cancer Treatment Centers
   7.7. Market Attractiveness Analysis
8. East Asia CAR T-Cell Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   8.1. Key Highlights
   8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       8.2.1. By Country
       8.2.2. By Product
       8.2.3. By Indication
       8.2.4. By End User
   8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
       8.3.1. China
       8.3.2. Japan
       8.3.3. South Korea
   8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2023 - 2031
       8.4.1. Yescarta (axicabtagene ciloleucel)
       8.4.2. Kymriah (tisagenlecleucel)
       8.4.3. JCAR017 (lisocabtagene maraleucel)
       8.4.4. bb2121
   8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       8.5.1. Relapsed Large B-cell Lymphoma
       8.5.2. Acute Lymphoblastic Leukemia (ALL)
       8.5.3. Multiple Myeloma
   8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2023 - 2031
       8.6.1. Car T-Cell Therapy at Hospitals
       8.6.2. Car T-Cell Therapy at Cancer Treatment Centers
   8.7. Market Attractiveness Analysis
9. South Asia & Oceania CAR T-Cell Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   9.1. Key Highlights
   9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       9.2.1. By Country
       9.2.2. By Product
       9.2.3. By Indication
       9.2.4. By End User
   9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
       9.3.1. India
       9.3.2. Southeast Asia
       9.3.3. ANZ
       9.3.4. Rest of South Asia and Oceania
   9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2023 - 2031
       9.4.1. Yescarta (axicabtagene ciloleucel)
       9.4.2. Kymriah (tisagenlecleucel)
       9.4.3. JCAR017 (lisocabtagene maraleucel)
       9.4.4. bb2121
   9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       9.5.1. Relapsed Large B-cell Lymphoma
       9.5.2. Acute Lymphoblastic Leukemia (ALL)
       9.5.3. Multiple Myeloma
   9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2023 - 2031
       9.6.1. Car T-Cell Therapy at Hospitals
       9.6.2. Car T-Cell Therapy at Cancer Treatment Centers
   9.7. Market Attractiveness Analysis
10. Latin America CAR T-Cell Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   10.1. Key Highlights
   10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       10.2.1. By Country
       10.2.2. By Product
       10.2.3. By Indication
       10.2.4. By End User
   10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
       10.3.1. Brazil
       10.3.2. Mexico
       10.3.3. Rest of Latin America
   10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2023 - 2031
       10.4.1. Yescarta (axicabtagene ciloleucel)
       10.4.2. Kymriah (tisagenlecleucel)
       10.4.3. JCAR017 (lisocabtagene maraleucel)
       10.4.4. bb2121
   10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       10.5.1. Relapsed Large B-cell Lymphoma
       10.5.2. Acute Lymphoblastic Leukemia (ALL)
       10.5.3. Multiple Myeloma
   10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2023 - 2031
       10.6.1. Car T-Cell Therapy at Hospitals
       10.6.2. Car T-Cell Therapy at Cancer Treatment Centers
   10.7. Market Attractiveness Analysis
11. Middle East & Africa CAR T-Cell Therapy Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)
   11.1. Key Highlights
   11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2022
       11.2.1. By Country
       11.2.2. By Product
       11.2.3. By Indication
       11.2.4. By End User
   11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
       11.3.1. GCC Countries
       11.3.2. Egypt
       11.3.3. South Africa
       11.3.4. Northern Africa
       11.3.5. Rest of Middle East & Africa
   11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2023 - 2031
       11.4.1. Yescarta (axicabtagene ciloleucel)
       11.4.2. Kymriah (tisagenlecleucel)
       11.4.3. JCAR017 (lisocabtagene maraleucel)
       11.4.4. bb2121
   11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2023 - 2031
       11.5.1. Relapsed Large B-cell Lymphoma
       11.5.2. Acute Lymphoblastic Leukemia (ALL)
       11.5.3. Multiple Myeloma
   11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2023 - 2031
       11.6.1. Car T-Cell Therapy at Hospitals
       11.6.2. Car T-Cell Therapy at Cancer Treatment Centers
   11.7. Market Attractiveness Analysis
12. Competition Landscape
   12.1. Market Share Analysis, 2023
   12.2. Market Structure
       12.2.1. Competition Intensity Mapping By Market
       12.2.2. Competition Dashboard
   12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
       12.3.1. Gilead Sciences, Inc.
           12.3.1.1. Overview
           12.3.1.2. Segments and Products
           12.3.1.3. Key Financials
           12.3.1.4. Market Developments
           12.3.1.5. Market Strategy
       12.3.2. Novartis AG
       12.3.3. Celgene Inc.
       12.3.4. Bluebird bio, Inc.
13. Appendix
   13.1. Research Methodology
   13.2. Research Assumptions
   13.3. Acronyms and Abbreviations